{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:12:17Z","timestamp":1769559137234,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41577-020-00458-y","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T19:02:55Z","timestamp":1602010975000},"page":"645-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Do cross-reactive antibodies cause neuropathology in COVID-19?"],"prefix":"10.1038","volume":"20","author":[{"given":"Jakob","family":"Kreye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Momsen","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-7976","authenticated-orcid":false,"given":"Harald","family":"Pr\u00fcss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"458_CR1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","author":"P Horby","year":"2020","unstructured":"Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19 \u2014 preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2021436 (2020).","journal-title":"N. Engl. J. Med."},{"key":"458_CR2","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1056\/NEJMc2008597","volume":"382","author":"J Helms","year":"2020","unstructured":"Helms, J. et al. Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 382, 2268\u20132270 (2020).","journal-title":"N. Engl. J. Med."},{"key":"458_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa240","author":"RW Paterson","year":"2020","unstructured":"Paterson, R. W. et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain https:\/\/doi.org\/10.1093\/brain\/awaa240 (2020).","journal-title":"Brain"},{"key":"458_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.01.20143214","author":"C Franke","year":"2020","unstructured":"Franke, C. et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.07.01.20143214 (2020).","journal-title":"medRxiv"},{"key":"458_CR5","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.23.20160770","author":"J Mulder","year":"2020","unstructured":"Mulder, J. et al. Autoimmune encephalitis presenting with malignant catatonia in a 40-year-old male patient with Covid-19. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.07.23.20160770 (2020).","journal-title":"medRxiv"},{"key":"458_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/jnnp-2020-323678","volume":"91","author":"L Delamarre","year":"2020","unstructured":"Delamarre, L. et al. COVID-19-associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network. Neurol. Neurosurg. Psychiatry 91, 1004\u20131006 (2020).","journal-title":"Neurol. Neurosurg. Psychiatry"},{"key":"458_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.049","author":"J Kreye","year":"2020","unstructured":"Kreye, J. et al. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. Cell https:\/\/doi.org\/10.1016\/j.cell.2020.09.049 (2020).","journal-title":"Cell"},{"key":"458_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","volume":"182","author":"C Kreer","year":"2020","unstructured":"Kreer, C. et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell 182, 843\u2013854 (2020).","journal-title":"Cell"},{"key":"458_CR9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1474-4422(18)30244-8","volume":"17","author":"T Armangue","year":"2018","unstructured":"Armangue, T. et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 17, 760\u2013772 (2018).","journal-title":"Lancet Neurol."},{"key":"458_CR10","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/ana.23689","volume":"72","author":"H Pr\u00fcss","year":"2012","unstructured":"Pr\u00fcss, H. et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann. Neurol. 72, 902\u2013911 (2012).","journal-title":"Ann. Neurol."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-020-00458-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-020-00458-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-020-00458-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T21:37:31Z","timestamp":1633642651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-020-00458-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1038\/s41577-020-00458-y","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"6 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The DZNE and Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin have filed a patent application on therapeutic SARS-CoV-2 monoclonal antibodies on which J.K., S.M.R. and H.P. are named as inventors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}